Technical Analysis for BDRX - Biodexa Pharmaceuticals plc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | -3.90% | |
NR7 | Range Contraction | -3.90% | |
NR7-2 | Range Contraction | -3.90% | |
Narrow Range Bar | Range Contraction | -3.90% | |
Wide Bands | Range Expansion | -3.90% | |
180 Bearish Setup | Bearish Swing Setup | -4.68% | |
NR7 | Range Contraction | -4.68% |
Alert | Time |
---|---|
Down 5% | about 21 hours ago |
60 Minute Opening Range Breakdown | about 22 hours ago |
Down 3% | about 22 hours ago |
Down 2 % | about 22 hours ago |
Fell Below 20 DMA | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/13/2024
Biodexa Pharmaceuticals plc Description
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Tumor Schizophrenia Drug Delivery Psoriasis Glioblastoma Major Depressive Disorder Brain Tumor Glioma Treatment Of Major Depressive Disorder Drug Delivery Technology Glioblastoma Multiforme Diffuse Intrinsic Pontine Glioma Organ Transplant
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 220.25 |
52 Week Low | 4.71 |
Average Volume | 200,152 |
200-Day Moving Average | 22.59 |
50-Day Moving Average | 8.32 |
20-Day Moving Average | 6.02 |
10-Day Moving Average | 6.36 |
Average True Range | 1.02 |
RSI (14) | 47.92 |
ADX | 43.29 |
+DI | 29.01 |
-DI | 18.35 |
Chandelier Exit (Long, 3 ATRs) | 7.84 |
Chandelier Exit (Short, 3 ATRs) | 7.76 |
Upper Bollinger Bands | 7.64 |
Lower Bollinger Band | 4.40 |
Percent B (%b) | 0.47 |
BandWidth | 53.87 |
MACD Line | -0.53 |
MACD Signal Line | -0.73 |
MACD Histogram | 0.204 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.07 | ||||
Resistance 3 (R3) | 7.07 | 6.69 | 6.88 | ||
Resistance 2 (R2) | 6.69 | 6.40 | 6.69 | 6.81 | |
Resistance 1 (R1) | 6.30 | 6.22 | 6.11 | 6.30 | 6.75 |
Pivot Point | 5.92 | 5.92 | 5.83 | 5.92 | 5.92 |
Support 1 (S1) | 5.53 | 5.63 | 5.34 | 5.52 | 5.07 |
Support 2 (S2) | 5.15 | 5.44 | 5.15 | 5.01 | |
Support 3 (S3) | 4.76 | 5.15 | 4.95 | ||
Support 4 (S4) | 4.75 |